Serum Level of the Soluble Form of the CD30 Molecule Identifies Patients With Hodgkin's Disease at High Risk of Unfavorable Outcome

Abstract

Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin's disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration at diagnosis in relation to the other recognized prognostic parameters in 303 patients with HD observed in three different institutions between 1984 and 1996. sCD30 levels were correlated with stage, presence of B symptoms, and tumor burden. High sCD30 levels entailed a higher risk of poor outcome, and the event-free survival (EFS) probability at 5 years for patients with sCD30 levels ≥100 and less than 100 U/mL was 59.9% (95% confidence interval [CI], 40.6% to 65.9%) and 87.5% (95% CI, 81.5% to 91.6%), respectively (P < .001). On the basis of the results of univariate analysis of 14 pretreatment characteristics, we included five prognostic factors (high sCD30 serum level, stage III-IV, B symptoms, low hemoglobin level, and age ≥50 years) into a multivariate model. High sCD30 and advanced stage were independently associated with an unfavorable prognosis. Their combined evaluation identified patients at high risk (stages III and IV and sCD30 ≥100 U/mL: EFS, 46.9%) and low risk (stages I and II with sCD30 <100 U/mL: EFS, 88.7%) of treatment failure (P < .001). We conclude that the combined evaluation of sCD30 serum level and stage at presentation identifies patients with HD at high risk of an unfavorable outcome.

Serum level of soluble CD30 correlates with the aggressiveness of adult T‐cell leukemia/lymphoma

“…From the relationship between elevation of serum sCD30 levels and clinical stage, it may be possible to identify patients with a very high or very low risk of treatment failure with standard therapy. ( 16,17 )…”

“…In ALCL and Hodgkin's disease (HD), elevated levels of sCD30 in the sera of patients are correlated with a poor prognosis, perhaps because a high level of sCD30 reflects a high tumor burden or because sCD30 blocks the biologic effects of CD30L. ( 15–17 ) Moreover, sCD30 is detectable in the sera of ATL patients. ( 11 ) In this study, we investigated the clinical significance of the membrane type of CD30 (mCD30) expression and serum sCD30 levels in ATL.…”

Retracted: Transactivation of the ICAM‐1 gene by CD30 in Hodgkin's lymphoma

“…Supershift assay of NF-jB DNA binding complex in nuclear extracts from KM-H2 cells was also carried out. Where indicated, appropriate antibodies were added to the reaction mixture (lanes [13][14][15][16].…”

“…13 Increased serum levels of soluble CD30 correlate with disease activity and thus bear prognostic significance in HL. 14 A later study, however, showed that CD30 was expressed not only on H/RS cells but also on a subset of large cell non-Hodgkin's lymphomas, activated lymphocytes and virus-infected lymphocytes. 15 In contrast, expression of its ligand CD30L is broader, being expressed on lymphocytes, neutrophils and eosinophils as well as activated monocytes/macrophages.…”

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

“…PatientsÕ therapy and response assessment were previously described (7). sCD30 assay sCD30 levels were determined in serum samples stored at )20°C by a sandwich enzyme-linked immunosorbent assay [CD30 (Ki-1 antigen) ELI-SA, DAKO, Glostrup, Denmark], according to manufacturer instructions, as previously described (23).…”